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Abstract  Shigella  ﬂexneri  is  divided  into  13  serotypes  based  on  the  combination  of
antigenic determinants  present  in  the  O-antigen.  A  new  O-antigen  modiﬁcation  with  phospho-
ethanolamine  has  been  identiﬁed.  The  presence  of  this  antigenic  determinant  (called  E1037)
is recognized  by  monoclonal  antibody  MASF  IV-1.  Given  the  increasing  incidence  of  these  new
variants  and  the  difﬁculty  in  supplying  the  monoclonal  antibody  to  our  country,  we  produced
a polyclonal  antiserum  (AA479)  through  immunization  with  a  S.  ﬂexneri  Xv  strain.  The  anti-
serum speciﬁcity  was  assessed  by  slide  agglutination  against  isolates  from  clinical  cases  and  a
culture collection  representing  all  Shigella  serotypes.  The  results  obtained  demonstrated  a  100%
correlation between  AA479  absorbed  antiserum  and  monoclonal  antibody  MASF  IV-1.  The  avail-
ability of  AA479  antiserum  in  every  public  hospital  in  Argentina  will  allow  us  to  identify  atypical
S. ﬂexneri  isolates  in  order  to  strengthen  Shigella  surveillance  in  our  country  and  to  compare
with global  epidemiological  data.
© 2014  Asociación  Argentina  de  Microbiología.  Published  by  Elsevier  España,
S.L.U. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE Antisuero  AA479:  nuevo  reactivo  para  la  serotipiﬁcación  de  variantes  atípicas  de
Shigella  ﬂexneri;
Variantes  atípicas;
Antisuero  policlonal;
Serotipiﬁcación
Shigella  ﬂexneri
Resumen  Shigella  ﬂexneri  se  divide  en  al  menos  13  serotipos  sobre  la  base  de  la  combinación
de determinantes  antigénicos  presentes  en  el  antígeno  O.  Se  identiﬁcó  una  nueva  modiﬁcación
del antígeno  O  con  fosfoetanolamina.  La  presencia  de  este  determinante  antigénico  (deno-
minado E1037)  es  reconocida  por  el  anticuerpo  monoclonal  MASF  IV-1.  Teniendo  en  cuenta  la
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incidencia  creciente  de  estas  nuevas  variantes  y  la  diﬁcultad  en  la  provisión  del  anticuerpo
monoclonal  para  nuestro  país,  se  elaboró  un  antisuero  de  tipo  policlonal  (AA479)  mediante
la inmunización  con  un  cultivo  de  S.  ﬂexneri  Xv.  La  especiﬁcidad  del  antisuero  se  evaluó  por
aglutinación  en  lámina  con  aislamientos  clínicos  y  cultivos  de  colección,  con  lo  que  quedaron
representados  todos  los  serotipos  de  Shigella. Los  resultados  obtenidos  demostraron  una  corre-
lación del  100%  entre  el  antisuero  AA479  absorbido  y  el  anticuerpo  monoclonal  MASF  IV-1.
La disponibilidad  del  antisuero  AA479  en  todos  los  hospitales  públicos  de  Argentina  permitirá
identiﬁcar  los  aislamientos  atípicos  de  S.  ﬂexneri; de  esta  forma  se  podrá  fortalecer  la  vigilancia
de Shigella  en  nuestro  país  y  comparar  con  los  datos  epidemiológicos  a  nivel  global.
© 2014  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,
S.L.U. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
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Shigella  infections  are  a  major  health  problem  world-
wide,  mainly  in  developing  countries.  Approximately  160
million  shigellosis  cases  have  been  estimated  per  year
around  the  globe  by  the  World  Health  Organization  with  the
majority  involving  children  under  ﬁve  years  of  age8,11.
Shigella  ﬂexneri  is  the  prevalent  species  in  develop-
ing  countries,  particularly  in  Argentina  where  70%  of  the
Shigella  infections  are  caused  by  S.  ﬂexneri  and  about
25%  by  S.  sonnei7.  In  Argentina,  Shigella  spp.  has  been  iden-
tiﬁed  by  the  Laboratory  Surveillance  System  (Ministry  of
Health),  as  one  of  the  main  causative  bacterial  agents
of  diarrhea2.
In  order  to  establish  the  diversity  of  the  circulating
serotypes  and  their  distribution  in  time  and  space,  it  is
necessary  to  determine  the  antigenic  characteristics  of  the
Shigella  strains  in  different  regions.  For  this  reason,  in
Argentina,  epidemiological  surveillance  is  performed  within
the  context  of  the  National  Network  for  Diarrhea  and  Food-
borne  Pathogens  (Diarrhea  Network)  through  serotyping  with
the  antisera  produced  by  the  Servicio  Antígenos  y  Antisueros
from  the  Instituto  Nacional  de  Producción  de  Biológicos
(INPB)  -- ANLIS  ‘‘Dr.  Carlos  G.  Malbrán’’.
The  genus  Shigella  comprises  four  species:  S.  dysen-
teriae,  S.  ﬂexneri,  S.  boydii  and  S.  sonnei.  Except  for
S.  sonnei, each  species  contains  multiple  serotypes  based  on
the  structure  of  the  O-antigen.  S.  dysenteriae  and  S.  boydii
have  been  subdivided  into  15  and  20  serotypes,  respectively.
In  the  serotyping  scheme  currently  in  use,  S.  ﬂexneri  is
divided  into  13  serotypes  based  on  the  combination  of  the
type-speciﬁc  antigen  (I,  II,  III,  IV,  V,  VI)  and  the  presence  of
one  or  more  group  antigens  (3,4--6--7,8)3,9.  All  S.  ﬂexneri
serotypes  (except  S.  ﬂexneri  6)  share  the  backbone  of  the
basic  O-antigen  repeat  unit,  which  is  a  tetrasaccharide  con-
sisting  of  a  single  N-acetyl  glucosamine  and  three  rhamnose
residues.  This  basic  structure  is  referred  to  as  serotype  Y
and  the  addition  of  glucosyl  and/or  O-acetyl  groups  to  dif-
ferent  sugars  in  the  tetrasaccharide  unit  forms  the  basis  of
serotype  conversion.  The  genes  involved  in  the  biosynthe-
sis  of  the  tetrasaccharide  are  located  in  the  chromosome
and  the  O-antigen  modiﬁcation  genes  known  to  date  are
encoded  by  temperate  bacteriophages  or  prophages  which
are  integrated  into  the  conserved  sites  of  the  host  S.  ﬂexneri
genome1.
In recent  years,  the  emergence  of  atypical  S.  ﬂexneri  has
been  reported,  such  as  the  provisionally  called  S.  ﬂexneri  Xv,
S.  ﬂexneri  Yv  and  S.  ﬂexneri  4av6,10--12,15.  All  these  strains
showed  agglutination  with  monoclonal  antibody  MASF  IV-1,
t
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fcenses/by-nc-nd/4.0/).
hich  binds  to  the  antigenic  determinant  E1037  not  cov-
red  in  the  S.  ﬂexneri  serotyping  scheme  currently  in  use.
he  MASF  IV-1  positive  phenotype  involves  the  presence  of
 phosphoethanolamine  (PEtN)  group  attached  to  at  least
ne  rhamnose  of  the  tetrasaccharide,  due  to  the  activ-
ty  of  the  PEtN--transferase  encoded  in  the  plasmidic  gene
pt-O11.
Considering  that  atypical  S.  ﬂexneri  (E1037  positive)  iso-
ates  have  been  detected  in  our  country  since  2009  and  in
iew  of  the  difﬁculty  in  supplying  the  antibody,  we  have
roduced  a  polyclonal  antiserum  (AA479)  to  allow  the  iden-
iﬁcation  of  such  bacterial  strains  and  to  strengthen  Shigella
urveillance  in  Argentina.
A randomly  selected  culture  of  S.  ﬂexneri  Xv  (#479/09
ulture)  was  used  for  the  production  of  rabbit  polyclonal
ntiserum  AA479  (anti-PEtN  antiserum).  The  purity  of  the
acteria,  the  biochemical  identiﬁcation  and  the  morphol-
gy  of  the  colony  (smoothness)  were  tested.  In  order  to
emove  thermolabile  surface  antigens,  the  immunizing  sus-
ension  was  prepared  by  heat  denatured  whole  cells  with  a
oncentration  of  approximately  5  ×  109 bacteria/ml.
New  Zealand  White  rabbits,  8  weeks  old  (approximately
.5  kg),  were  immunized  with  a  ﬁrst  intramuscular  0.5  ml
ose  and  then  a series  of  intravenous  inoculation  of  0.5,
.0,  2.0,  and  two  doses  of  4.0  ml  administered  at  3--4  day
nterval.  The  rabbits  were  exsanguinated  by  cardiac  punc-
ure  7--10  days  after  the  last  injection.  Then,  the  serum  was
tored  at  4 ◦C  with  10%  glycerin  phenolized  saline  solution
s  a  preservative.
Thirty-four  S.  ﬂexneri  strains  (32  S.  ﬂexneri  Xv,  1 S.
exneri  4av  and  1  nontypeable  S.  ﬂexneri),  which  showed
gglutination  with  monoclonal  antibody  MASF  IV-1,  were
sed  to  control  the  AA479  antiserum.  All  these  studied
trains  were  received  (over  a  one  year  span),  between
009  and  2010,  by  the  National  Reference  Laboratory
Servicio  Enterobacterias  from  the  Instituto  Nacional  de
nfermedades  Infecciosas  (INEI)  --  ANLIS  ‘‘Dr.  Carlos  G.
albrán’’)  from  human  stool  samples.  Sixty-seven  Shigella
trains  from  the  Antigens  and  Antisera  Service  Collec-
ion,  including  all  currently  recognized  serotypes  of  the
our  species  (15  S.  dysenteriae, 19  S.  boydii, 2  S.  son-
ei  and  31  S.  ﬂexneri)  and  S.  ﬂexneri  7a5,14 were  also
sed  for  the  antiserum  control.  All  cultures  were  biochem-
cally  characterized  as  Shigella  spp.  in  accordance  with
he  procedures  previously  described4 and  kept  at  −70 ◦C
n  tryptic  soy  broth  with  glycerol.  Serotyping  was  per-
ormed  by  a  slide  agglutination  assay  using  speciﬁc  antisera
38  C.A.  van  der  Ploeg  et  al.
Table  1  Agglutination  reactions  of  AA479  antiserum.
S.  ﬂexneri  No.  of  isolates  Titer  of  AA479  antiserum
Unabsorbed  Absorbed
1aa 2  10  −
1ba 2  −  −
2aa 1  −  −
2ba 1  40  −
3aa 4  40  −
3ba 1  10  −
4aa 6  10  −
4avb 3  40  40
4ba 2  10  −
5aa 1  40  −
5ba 1  40  −
6a 2  −  −
7ac 1  −  −
Xa 2  40  −
Xvd 32  40e--80e 40
Ya 3  20  −
Nontypeabled 1  40  40
The agglutination absence with the 1/10 diluted antiserum is considered negative (−).
The cultures corresponding to the species S. boydii,  S. dysenteriae and S. sonnei were negative in the 1/5 dilution of AA479 antiserum
without absorption.
a Cultures belonging to the Antigens and Antisera Collection.
b One of the isolates is from a clinical source, the other two belong to the Antigens and Antisera Collection.
c S. ﬂexneri 7a culture was kindly provided by Dr. K. Talukder (International Centre for Diarrhoeal Disease Research, Bangladesh).
d Clinical isolates. Nontypeable is the isolate that showed no agglutination with any of the three known group factors (3,4--6--7,8) or
as 40
f
c
S
a
f
m
(
t
w
g
n
r
t
s
(
(
3
o
(
t
A
t
(
c
b
t
ﬂ
n
I
o
s
t
X
t
o
t
t
r
b
t
s
b
N
s
u
o
swith the type-speciﬁc antigen.
e The titer corresponding to the antiserum without absorption w
or  all  types  and  group-factor  antigens  (INPB)  and  mono-
lonal  antibody  against  S.  ﬂexneri  (MASF  IV-1;  Reagensia  AB,
weden).
Cell  suspensions  were  employed  for  the  titration  of  AA479
ntiserum.  Bacterial  suspensions  were  prepared  directly
rom  cultures  grown  at  37 ◦C  for  18  h  with  1.0  ml  of  0.5%  for-
alinized  physiological  saline  solution.  Twenty  microliters
20  l)  of  the  bacterial  suspension  and  20  l  of  serial  dilu-
ions  of  antiserum  were  placed  on  a  glass  slide  and  mixed
ith  the  microbiological  loop  or  stick.  The  slide  was  tilted
ently  back  and  forth  for  1  min  and  the  appearance  or
on-appearance  of  agglutination  was  observed  with  an  indi-
ect  intense  light.  The  titer  was  deﬁned  as  the  inverse  of
he  highest  dilution  giving  a  positive  result  3+  (large  and
mall  clumps  against  a  slightly  cloudy  background)  or  4+
large  clumps  against  a  clear  background).
The  unabsorbed  antiserum  showed  a  strong  reaction
titer  40--80)  with  the  collection  cultures  of  S.  ﬂexneri  2b,
a,  4av,  5a,  5b  and  X  serotypes,  as  well  as  clinical  isolates
f  S.  ﬂexneri  4av,  Xv  and  nontypeable  serotypes  (Table  1).
AA479  antiserum  was  subjected  to  a  puriﬁcation  process
absorption  process)  for  the  removal  of  heterologous  agglu-
inins  in  accordance  with  a  previously  described  procedure4.
n  overnight  growth  culture  of  S.  ﬂexneri  X  at  37 ◦C  in  tryp-
ic  soy  agar  was  used  as  an  absorbent  in  a  ratio  of  1  plate
150  mm  diameter)  per  4  ml  of  antiserum.  The  mixture  of
ells  and  serum  was  incubated  for  2  h  at  50 ◦C  in  a  water
ath;  then,  the  absorbed  antiserum  was  removed  by  cen-
rifugation  at  12,000  rpm  for  30  min.
t
i
a or 80 according to the evaluated isolate.
The  absorbed  antiserum  was  speciﬁc  for  atypical  S.
exneri  cultures,  including  those  belonging  to  4av,  Xv  and
ontypeable  serotypes  (Table  1).
With  regard  to  the  correlation  between  AA479  and  MASF
V-1,  a  100%  concordance  between  both  reagent  results  was
bserved  (Table  2).
Having  considered  that  the  emergence  of  new  S.  ﬂexneri
erotypes  is  not  unusual10,12,13,15,  that  rapid  dissemination  of
hese  variants  may  occur  and  that  multiresistant  S.  ﬂexneri
v  strains  have  been  detected  in  China15, it  is  necessary
o  keep  the  epidemiological  surveillance  of  the  serotypes
f  this  species  updated.  Likewise,  the  information  about
he  distribution  of  the  different  serotypes  remains  impor-
ant  to  the  proposal  of  the  World  Health  Organization
egarding  a vaccine  development  to  decrease  the  world  mor-
idity  caused  by  Shigella  as  well  as  having  the  knowledge
hat  acquired  immunity  against  this  organism  infection  is
erotype-speciﬁc8.
AA479  antiserum  production  and  its  immediate  distri-
ution  to  the  public  hospitals  belonging  to  the  Diarrhea
etwork  enabled  to  detect  in  2009,  the  appearance  and  dis-
emination  of  S.  ﬂexneri  Xv  (Vin˜as,  van  der  Ploeg,  et  al.,
npublished  data).  This  emerging  serotype  represented  30%
f  the  S.  ﬂexneri  isolates  analyzed  in  2010  and  became  the
econd  serotype  in  importance  after  S.  ﬂexneri  2,  the  his-
orically  predominant  serotype.
S.  ﬂexneri  unabsorbed  antisera  are  characterized  by  hav-
ng  cross-reactivity  with  all  of  S.  ﬂexneri  serotype  cultures
nd  by  the  titer  decrease  of  at  least  one  dilution  after
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Table  2  Comparison  of  the  results  obtained  with  AA479  antiserum  and  monoclonal  antibody  MASF  IV-1.
Serotype  No.  of  isolates  AA479  absorbeda MASF  IV-1
S.  dysenteriae  1--15 15  −  −
S. boydii  1--18  and  20  19  −  −
S. sonnei  FI  and  FII  2  −  −
S. ﬂexneri
1a--1b  2--2  −  −
2a--2b 1--1  −  −
3a--3b 4--1  −  −
4a--4b 6--2  −  −
5a--5b 1--1 −  −
6 2  −  −
7a 1  −  −
X 2  −  −
Y 3  −  −
S. ﬂexneri  4avb 3  +  +
S. ﬂexneri  Xvc 32  +  +
S. ﬂexneri  nontypeablec 1  +  +
a Absorbed AA479 antiserum was used at a dilution of 1/40, according to the titer expressed in Table 1.
b ng to
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c Clinical isolates. Nontypeable is the isolate that showed no agg
with the type-speciﬁc antigen.
the  absorption  process.  Nevertheless,  AA479  unabsorbed
antiserum  showed  cross-reactivity  with  only  some  of  the
S.  ﬂexneri  serotypes  and  its  titer  did  not  decrease  after
absorption.  These  results  may  be  due  to  the  structural  dif-
ference  of  the  PEtN  group  regarding  the  other  O-antigen
determinants,  mostly  glucosyl  and  rhamnose  residues.
The  concordance  between  the  results  obtained  with
the  AA479  polyclonal  antiserum  and  monoclonal  antibody
MASF-IV-1  suggests  that  both  reagents  recognize  the  same
antigenic  determinant  in  the  seroagglutination  test.  The
serological  behavior  observed  in  the  current  study  along
with  the  results  obtained  by  others  researchers6,11 leads  us
to  propose  the  epitope  E1037  as  a  novel  S.  ﬂexneri  group
factor  and  to  highlight  the  need  to  agree  on  a  serotyping
scheme  and  an  updated  nomenclature  including  the  new
strains  described.
Nowadays,  monoclonal  antibody  MASF  IV-1  is  the  only
available  reagent  for  the  detection  of  S.  ﬂexneri  E1037-
antigen  carrier  isolates,  which  is  neither  accessible  for  use
in  our  country  nor  in  most  Latin  American  countries.  Hav-
ing  considered  that  the  correlation  between  the  antibody
and  the  AA479  antiserum  was  100%,  the  indistinct  use  of
one  or  the  other  would  lead  to  obtain  comparable  informa-
tion  worldwide.  We  propose  AA479  antiserum  to  be  used  as  a
novel  serotype  marker  for  the  additional  characterization  of
S.  ﬂexneri  isolates  in  Argentina  as  well  as  in  Latin  America,
in  order  to  cooperate  with  the  epidemiological  surveillance
of  Shigella  spp.  in  the  region.
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